Pilot trial tests Decellularised Skin Grafts

Tissue Regenix, the RegenMed company focused on the development and commercialisation of acellular tissue replacement products to address the chronic global shortfalls in donor tissue availability, announces that its partner, NHS Blood and Transplant (NHSBT), has initiated a pilot study to evaluate the use of decellularised human donor skin grafts (dCELL® Human Dermis) in the treatment of chronic, non-healing wounds, utilising Tissue Regenix’s proprietary dCELL® technology.

The pilot study will be comprised of 20 patients with existing chronic wounds. Patients will be monitored over a 42-day period in order to assess the effectiveness of dCELL® Human Dermis in improving the closure of chronic wounds. The pilot study is designed to investigate the responsiveness of chronic wounds to determine the size of a larger, multi-centred study. Patients will continue to be monitored for up to six months following completion of the pilot study. The study, led by Mr Ardeshir Bayat, a NIHR clinician scientist in the field of plastic and reconstructive surgery with international expertise in wound healing research, will be carried out at the University Hospital of South Manchester (UHSM). The initial pilot study will be largely funded by the NHSBT.

"We are very excited by the prospect of this work. This new technology has the potential to help many patients with long term, chronic wounds. Our experience of running trials means that NHSBT should be able to use good clinical data to support the use of these new tissues across the NHS,"